Marie-Eve BeaulieuCSO at PEPTOMYCSpeaker
Dr. Beaulieu is the co-founder and Chief Scientific Officer at Peptomyc, a biotech company developing mini-protein therapeutics for cancer treatment. PhD in Pharmacology with a strong focus on structural biology of proteins, Marie-Eve has lead the preclinical pharmaceutical development of OMO-103, the first direct MYC inhibitor to successfully complete a clinical trial showing safety and clinical activity in human patients in 2022. Marie-Eve also contributed to design the company strategy, build the team and fundraised public >11MEur and private ~30MEur capital. She currently leads Peptomyc’s pipeline expansion activities and the chemistry, manufacturing and controls activities related to OMO-103. Marie-Eve has co-authored 8 patent applications, 31 peer-reviewed publications and 4 book chapters (ORCID 0000-0001-5224-8436). She was awarded several competitive fellowships (eg. MITACS, FRSQ postdoctoral awards, Worldwide Cancer Research grant) and contributed to the company’s scientific and business excellence as testified by several local and international awards (eg BioFit, Best company initiative at AJIEC, EIT Health Headstart, J&J StartUpSlam at BioEurope, and the highly competitive H2020 SME Instrument and EIC Accelerator awards).